BREAKING NEWS: Aurora Cannabis has acquired MedReleaf Australia for A$50 million in a cash and share deal.

The Canadian giant, which already owned 10% of the Australian firm, said full ownership of Indica Industries, which trades as MedReleaf Australia, “solidifies our position in this rapidly growing market”.

Russell Harding

Aurora will pay $9.45m in cash with the balance in Aurora shares.

In a statement, MedReleaf Australia co-founders Russell Harding and Nathan Davis said: “We’re proud to have built one of Australia’s leading medical cannabis companies, thanks to our main supplier Aurora, dedicated investors, and dynamic team.

“Through our vision, we’ve connected clinicians with patients nationwide, positively impacting thousands of lives. This transaction marks an important step for MedReleaf Australia’s ongoing growth, as we believe medical cannabis is now mainstream medicine, and we’re grateful to be part of that story.”

Aurora chief executive Miguel Martin described the acquisition as a “strategic milestone in Aurora’s global cannabis leadership”.

“[It] demonstrates our commitment to investing in markets that offer opportunities for sustainable and profitable growth,” he said. “We are excited to solidify our position in this rapidly growing market and the opportunity this transaction presents to us in accelerating our plans to deliver positive free cash flow in calendar 2024.”

According to the statement, MedReleaf Australia generated net revenue of approximately $40m in the year to December 31 2023 and was adjusted EBITDA and operating cash flow positive.

Data released by research firm NostraData last week showed MedReleaf captured almost one in five medicinal cannabis sales in Australia in 2023.

According to the Australian Securities and Investments Commission (ASIC), Harding owns 44% of Indica Industries, with Sativa Operations, a business owned by Davis, controlling 18%.

The company launched in early 2018, originally as a joint venture with Canadian firm MedReleaf Corp.

Aurora then acquired MedReleaf Corp for US$2.5 billion in May of that year, and has held a 10% stake in the local operation.

In an interview with Cannabiz in late 2020, Harding said MedReleaf Australia was “fortunate to have the support of Aurora on a range of levels and a good supply line”.

“You never know in this world what’s around the corner, but certainly at this point we’re comfortable with the relationship,” he said.

“I think it’s very much the case that some companies are skewing towards recreational cannabis, but Aurora still retains its strong focus on medical. It started as a medicinal cannabis company and it still is.”  

Auroras had also been a cornerstone investor in Cann Group but sold its remaining 12.5% stake in 2020.  

  • Cannabiz Premium members received a breaking news alert about this story, direct to their inbox, as it happened. To sign up for Cannabiz Premium, click here.     

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment